Isoprenoid Metabolism in Apicomplexan Parasites

Leah Imlay, Audrey R. Odom

Research output: Contribution to journalReview articlepeer-review

48 Scopus citations


Apicomplexan parasites include some of the most prevalent and deadly human pathogens. Novel antiparasitic drugs are urgently needed. Synthesis and metabolism of isoprenoids may present multiple targets for therapeutic intervention. The apicoplast-localized methylerythritol phosphate pathway for isoprenoid precursor biosynthesis is distinct from the mevalonate pathway used by the mammalian host, and this pathway is apparently essential in most Apicomplexa. In this review, we discuss the current field of research on production and metabolic fates of isoprenoids in apicomplexan parasites, including the acquisition of host isoprenoid precursors and downstream products. We describe recent work identifying the first methylerythritol phosphate pathway regulator in apicomplexan parasites, and introduce several promising areas for ongoing research into this well-validated antiparasitic target.

Original languageEnglish
Pages (from-to)37-50
Number of pages14
JournalCurrent Clinical Microbiology Reports
Issue number3-4
StatePublished - Dec 1 2014


  • Apicomplexa
  • Fosmidomycin
  • Isoprenoid
  • Metabolism
  • Methylerythritol phosphate (MEP) pathway
  • Plasmodium


Dive into the research topics of 'Isoprenoid Metabolism in Apicomplexan Parasites'. Together they form a unique fingerprint.

Cite this